share_log

Virios Therapeutics Received FDA Feedback On Requirements For Advancing Imc-2 (Combination Of Valacyclovir + Celecoxib) As A Treatment For Fatigue, Orthostatic Intolerance, And Other Symptoms Associated With Long Covid Illness

Virios Therapeutics Received FDA Feedback On Requirements For Advancing Imc-2 (Combination Of Valacyclovir + Celecoxib) As A Treatment For Fatigue, Orthostatic Intolerance, And Other Symptoms Associated With Long Covid Illness

Virios Therapeutics收到了美國食品藥品管理局關於推進Imc-2(伐昔洛韋+塞來昔布的組合)作爲疲勞、體位不耐受和其他與長期Covid疾病相關的症狀的治療的要求的反饋
Benzinga ·  01/02 07:09

Virios Therapeutics Received FDA Feedback On Requirements For Advancing Imc-2 (Combination Of Valacyclovir + Celecoxib) As A Treatment For Fatigue, Orthostatic Intolerance, And Other Symptoms Associated With Long Covid Illness

Virios Therapeutics收到了美國食品藥品管理局關於推進Imc-2(伐昔洛韋+塞來昔布的組合)作爲疲勞、體位不耐受和其他與長期Covid疾病相關的症狀的治療的要求的反饋

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論